版本:
中国

BRIEF-BiolineRx reports regulatory submissions of 3 Phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors

June 1 Bioline Rx Ltd:

* BiolineRx reports regulatory submissions of three phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors

* Bioline Rx - trials for pancreatic, gastric and non-small cell cancer expected to commence during second half of 2017, after receipt of regulatory approval Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐